摘要
目的评价舒肝宁注射液治疗黄疸型病毒性肝炎的疗效与安全性。方法检索PUBMED、Cochrane Library、万方、维普和CNKI中国期刊全文数据库2015年6月前已发表的关于舒肝宁注射液治疗黄疸型病毒性肝炎的随机临床对照试验研究。利用Revman5.0进行荟萃分析。结果共8项RCT(791例)纳入荟萃分析。两组有效率对比,差异无统计学意义(P>0.05)。试验组ALT、AST、TBIL治疗后改善率情况明显,差异均具有统计学意义(P<0.05)。治疗4周后,两组患者的ALT、AST对比,差异无统计学意义(P>0.05),试验组TBIL较对照组明显降低,差异具有统计学意义(P<0.05)。结论黄疸型病毒性肝炎患者应用舒肝宁注射液能改善临床症状,促进肝功能的恢复,对TBIL改善效果更明显,不良反应发生率较低。
Objective To evaluate the efcacy and safety of Shuganning injection in treating icteric viral hepatitis. Methods Correlated RCTs comparing shuganning injection in the treatment of the jaundice hepatitis was searched in PUBMED, Cochrane Library, WANFANG STATA, VIP and National Knowledge Infrastructure before June 2015. Revman5.0 software was used for the meta-analysis. Results A total of 8 RCT （791 cases） were included in the meta analysis. There was no statistical diference between the two groups （P 〉 0.05）. The rate of improvement of the test group after ALT, AST and TBIL was obvious, and the diference was statistically signifcant （P 〈 0.05）. After 4 weeks of treatment, the difference of ALT and AST in the two groups was not statistically signifcant （P 〉 0.05）. The TBIL in the test group was signifcantly lower than that in the control group, and the diference was statistically significant （P 〈 0.05）. Conclusion Shuganning injection therapy can improve the clinical symptoms of icteric viral hepatitis patients, and promote liver function recovery,especially in TBIL, with the lower adverse reaction rate.
出处
《中国继续医学教育》
2018年第5期153-155,共3页
China Continuing Medical Education
关键词
舒肝宁注射液
肝炎
荟萃分析
疗效
Shuganning injection
hepatitis
meta-analysis
efectiveness
